v3.3.1.900
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Cash flows from operating activities      
Net loss $ (26,733) $ (28,999) $ (27,953)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 7,220 5,572 4,335
Stock-based compensation expense 12,499 7,527 2,426
Charge related to execution of new lease agreement 884    
Loss on impairment and disposal of long-lived assets     811
Changes in operating assets and liabilities:      
(Increase) decrease in accounts receivable, net (625) 1,485 (1,587)
(Increase) decrease in advance to clients (875) (1,094) 415
(Increase) in prepaid expenses and other current assets (4,001) (374) (939)
Increase (decrease) in accounts payable 2,251 (2,565) 1,894
Increase in accrued compensation and related benefits 4,317 3,123 3,924
Increase in accrued expenses and other liabilities 1,216 2,978 1,762
Increase in deferred revenue 703 640 530
Increase in payments to clients (3,664) (826)  
(Increase) decrease in other assets and other liabilities, net (2,709) 153 (1,267)
Other 250 695 (33)
Net cash used in operating activities (9,267) (11,685) (15,682)
Cash flows from investing activities      
Purchases of property and equipment (4,096) (3,803) (2,367)
Capitalized content development cost expenditures (9,518) (7,150) (5,213)
Other (2,331) (29) (56)
Net cash used in investing activities (15,945) (10,982) (7,636)
Cash flows from financing activities      
Proceeds from issuance of common stock, net of offering costs 117,112 100,302  
Proceeds from exercise of stock options 5,336 2,282 325
Proceeds from revolving line of credit   5,000  
Payment on revolving line of credit   (5,000)  
Proceeds from issuance of Series D redeemable convertible preferred stock, net of issuance costs     4,994
Other (436)   (179)
Net cash provided by financing activities 122,012 102,584 5,140
Net increase (decrease) in cash and cash equivalents 96,800 79,917 (18,178)
Cash and cash equivalents, beginning of period 86,929 7,012 25,190
Cash and cash equivalents, end of period 183,729 86,929 7,012
Supplemental disclosure of non-cash investing and financing activities      
Accretion of issuance costs on redeemable convertible preferred stock   89 347
Accrued capital expenditures $ 415 557 216
Deferred offering costs included in accounts payable and accrued expenses     (1,057)
Issuance of Series D redeemable convertible preferred stock warrant in connection with revolving line of credit     $ 107
Common stock granted in exchange for consulting services received   $ 55